<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03393494</url>
  </required_header>
  <id_info>
    <org_study_id>PRG-NY-17-008</org_study_id>
    <nct_id>NCT03393494</nct_id>
  </id_info>
  <brief_title>Bioequivalence Study of Two Treatments in the Treatment of Acne Vulgaris on the Face</brief_title>
  <official_title>Multi-Center, Double-Blind, Randomized, Vehicle-Controlled, Parallel-Group Study to Compare Perrigo's Adapalene/BP Gel to Galderma's Epiduo (Adapalene/BP) Gel, and Both Treatments to a Vehicle Control in the Treatment of Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Padagis LLC</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Padagis LLC</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the safety and efficacy of Perrigo's product to an FDA approved product for the&#xD;
      treatment of Acne Vulgaris&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 13, 2017</start_date>
  <completion_date type="Actual">January 5, 2019</completion_date>
  <primary_completion_date type="Actual">September 30, 2018</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline in the Papules and Pustules Lesion Count</measure>
    <time_frame>Day 1 to week 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Percent Change From Baseline in the Open and Closed Comedones Lesion Count</measure>
    <time_frame>Day 1 to week 12</time_frame>
    <description>Per protocol population</description>
  </primary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">825</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Perrigo active</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Test product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Reference active</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>RLD product</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Perrigo placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo product</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Adapalene and Benzoyl Peroxide Topical Gel</intervention_name>
    <description>Test product</description>
    <arm_group_label>Perrigo active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Epiduo Topical Product</intervention_name>
    <description>RLD product</description>
    <arm_group_label>Reference active</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo gel</description>
    <arm_group_label>Perrigo placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Signed IRB approved written informed consent/assent&#xD;
&#xD;
          2. 12 to 40 years of age, inclusive.&#xD;
&#xD;
          3. Clinical diagnosis of facial acne vulgaris with an inflammatory lesion (papules and&#xD;
             pustules) count of 20-50, inclusive and a non-inflammatory (open and closed comedones)&#xD;
             lesion count of 25-100 inclusive and no more than 2 nodulocystic lesions (e.g.,&#xD;
             nodules and cysts) including those present on the nose.&#xD;
&#xD;
          4. Baseline Investigator's Global Assessment Score of 3 (moderate) or 4 (severe) on a&#xD;
             severity scale of 0 to 4.&#xD;
&#xD;
          5. Females of child bearing potential (excluding women who are surgically sterilized&#xD;
             (tubal ligation or bilateral oophorectomy or hysterectomy) or post-menopausal for at&#xD;
             least 2 years), in addition to having a negative urine pregnancy test at Visit&#xD;
             1/Day1(Baseline), must be willing to use an acceptable form of birth control during&#xD;
             the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Pregnant, breastfeeding or planning a pregnancy within the period of their study&#xD;
             participation period.&#xD;
&#xD;
          2. Presence of more than 2 facial Nodulocystic lesions.&#xD;
&#xD;
          3. Presence of any other facial skin condition that, in the Investigator's opinion, might&#xD;
             interfere with acne vulgaris diagnosis and/or evaluations&#xD;
&#xD;
          4. Any uncontrolled, chronic or serious disease or medical condition that would prevent&#xD;
             participation in a clinical trial, or, in judgment of the investigator, would put the&#xD;
             subject at undue risk or might confound the study assessments&#xD;
&#xD;
          5. Excessive facial hair that would interfere with the diagnosis or assessment of acne&#xD;
             vulgaris.&#xD;
&#xD;
          6. History of unresponsiveness to topical adapalene and/or benzoyl peroxide therapy.&#xD;
&#xD;
          7. Currently using any product containing adapalene and/or benzoyl peroxide and/or&#xD;
             belonging to the same family.&#xD;
&#xD;
          8. History of hypersensitivity or allergy to adapalene, benzoyl peroxide, retinoids&#xD;
             and/or any ingredient in the study medication.&#xD;
&#xD;
          9. Use of medications known to exacerbate acne&#xD;
&#xD;
         10. Start or change within 3 months (90 days) of Visit 1 and throughout the study&#xD;
&#xD;
         11. Use of medicated make-up throughout the study and significant change in the use of&#xD;
             consumer products within 30 days (1 month) of study entry and throughout the study&#xD;
&#xD;
         12. Subject consumes excessive alcohol, abuses drugs, or has a condition that could&#xD;
             compromise the subject's ability to comply with study requirements.&#xD;
&#xD;
         13. Subjects who in the opinion of the investigator, are unlikely to be able to follow the&#xD;
             restrictions of the protocol and complete the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>12 Years</minimum_age>
    <maximum_age>40 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Dermatology Consultants</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>January 3, 2018</study_first_submitted>
  <study_first_submitted_qc>January 3, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">January 8, 2018</study_first_posted>
  <results_first_submitted>November 13, 2020</results_first_submitted>
  <results_first_submitted_qc>December 9, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">January 5, 2021</results_first_posted>
  <disposition_first_submitted>October 8, 2019</disposition_first_submitted>
  <disposition_first_submitted_qc>December 9, 2020</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">January 5, 2021</disposition_first_posted>
  <last_update_submitted>November 5, 2021</last_update_submitted>
  <last_update_submitted_qc>November 5, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 8, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adapalene</mesh_term>
    <mesh_term>Benzoyl Peroxide</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03393494/Prot_001.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 28, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/94/NCT03393494/SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Test Product</title>
          <description>Adapalene and Benzoyl Peroxide Topical Gel</description>
        </group>
        <group group_id="P2">
          <title>Reference Product</title>
          <description>Epiduo Topical Gel</description>
        </group>
        <group group_id="P3">
          <title>Placebo Product</title>
          <description>Placebo gel</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="329"/>
                <participants group_id="P2" count="331"/>
                <participants group_id="P3" count="165"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="261"/>
                <participants group_id="P2" count="256"/>
                <participants group_id="P3" count="140"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="68"/>
                <participants group_id="P2" count="75"/>
                <participants group_id="P3" count="25"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Perrigo Active</title>
          <description>Test product&#xD;
Adapalene and Benzoyl Peroxide Topical Gel: Test product</description>
        </group>
        <group group_id="B2">
          <title>Reference Active</title>
          <description>RLD product&#xD;
Epiduo Topical Product: RLD product</description>
        </group>
        <group group_id="B3">
          <title>Perrigo Placebo</title>
          <description>placebo product&#xD;
Placebo: Placebo gel</description>
        </group>
        <group group_id="B4">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="329"/>
            <count group_id="B2" value="331"/>
            <count group_id="B3" value="165"/>
            <count group_id="B4" value="825"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="160"/>
                    <measurement group_id="B2" value="161"/>
                    <measurement group_id="B3" value="76"/>
                    <measurement group_id="B4" value="397"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="169"/>
                    <measurement group_id="B2" value="170"/>
                    <measurement group_id="B3" value="89"/>
                    <measurement group_id="B4" value="428"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="117"/>
                    <measurement group_id="B2" value="129"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="315"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="212"/>
                    <measurement group_id="B2" value="202"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="510"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="126"/>
                    <measurement group_id="B2" value="120"/>
                    <measurement group_id="B3" value="53"/>
                    <measurement group_id="B4" value="299"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="203"/>
                    <measurement group_id="B2" value="211"/>
                    <measurement group_id="B3" value="112"/>
                    <measurement group_id="B4" value="526"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="13"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="23"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="51"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="30"/>
                    <measurement group_id="B4" value="129"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="241"/>
                    <measurement group_id="B2" value="256"/>
                    <measurement group_id="B3" value="122"/>
                    <measurement group_id="B4" value="619"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="21"/>
                    <measurement group_id="B2" value="19"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline in the Papules and Pustules Lesion Count</title>
        <time_frame>Day 1 to week 12</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Perrigo Active</title>
            <description>Test product&#xD;
Adapalene and Benzoyl Peroxide Topical Gel: Test product</description>
          </group>
          <group group_id="O2">
            <title>Reference Active</title>
            <description>RLD product&#xD;
Epiduo Topical Product: RLD product</description>
          </group>
          <group group_id="O3">
            <title>Perrigo Placebo</title>
            <description>placebo product&#xD;
Placebo: Placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in the Papules and Pustules Lesion Count</title>
          <population>Per protocol population</population>
          <units>percentage of lesion change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="68.18" spread="28.96"/>
                    <measurement group_id="O2" value="63.56" spread="31.57"/>
                    <measurement group_id="O3" value="50.72" spread="35.12"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <param_type>Equivalence ratio</param_type>
            <param_value>107</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>97.8</ci_lower_limit>
            <ci_upper_limit>112.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Percent Change From Baseline in the Open and Closed Comedones Lesion Count</title>
        <description>Per protocol population</description>
        <time_frame>Day 1 to week 12</time_frame>
        <population>Per protocol population</population>
        <group_list>
          <group group_id="O1">
            <title>Perrigo Active</title>
            <description>Test product&#xD;
Adapalene and Benzoyl Peroxide Topical Gel: Test product</description>
          </group>
          <group group_id="O2">
            <title>Reference Active</title>
            <description>RLD product&#xD;
Epiduo Topical Product: RLD product</description>
          </group>
          <group group_id="O3">
            <title>Perrigo Placebo</title>
            <description>placebo product&#xD;
Placebo: Placebo gel</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Percent Change From Baseline in the Open and Closed Comedones Lesion Count</title>
          <description>Per protocol population</description>
          <population>Per protocol population</population>
          <units>percentage of lesion change</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="202"/>
                <count group_id="O2" value="218"/>
                <count group_id="O3" value="120"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="62.75" spread="28.09"/>
                    <measurement group_id="O2" value="60.78" spread="33.73"/>
                    <measurement group_id="O3" value="43.45" spread="36.30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>provides 85% power of success</non_inferiority_desc>
            <p_value>0.05</p_value>
            <method>Fieller's method</method>
            <param_type>Equivalence ratio</param_type>
            <param_value>104</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>94.1</ci_lower_limit>
            <ci_upper_limit>108.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>12 Weeks</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Perrigo Active</title>
          <description>Test product&#xD;
Adapalene and Benzoyl Peroxide Topical Gel: Test product</description>
        </group>
        <group group_id="E2">
          <title>Reference Active</title>
          <description>RLD product&#xD;
Epiduo Topical Product: RLD product</description>
        </group>
        <group group_id="E3">
          <title>Perrigo Placebo</title>
          <description>placebo product&#xD;
Placebo: Placebo gel</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="2" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Cervical Radiculopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Pregnancy, puerperium and perinatal conditions</title>
            <event_list>
              <event>
                <sub_title>Abortion spontaneous</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" events="1" subjects_affected="1" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="329"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="331"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="165"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonathan Schwartz</name_or_title>
      <organization>Perrigo</organization>
      <phone>718-960-9900</phone>
      <email>jonathan.schwartz@perrigo.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

